Abstracts

in control of tumorigenic processes, by using tumour infiltrating lymphocytes. How this process works is still being established, however there remains a potential target for cancer specific immunomodulatory treatment regimens.

Aim (1) To identify tumour specific MHC class I phosphopeptide antigens on lymphoblastoid cell lines LCL's (an in vitro model for PTLD) as well as hepatic tumour tissues. (2) T-cells are immune cells which are notoriously difficult to maintain in long-term culture and as a result it is difficult to establish an ‘off the shelf’ T-cell product, however the aim of this project was to explore potential modalities for capturing the T-cell receptor (TCR), important in recognising tumour specific antigens and the resultant product could be used to establish a non patient-specific, but tumour specific product.

Patients and methods Paediatric and adult patients were identified with hepatic malignancy and consented as per current policy. Cells were isolated and tumour specific phosphopeptide antigens were identified. These provide the targets for T-cells, and specifically TCRs. Having identified these antigens, modalities have been explored for expanding these cells. Hybridoma technology is long established in immortalising B-cells, and this study aims to explore its potential with immortalisation of T-cells.

Results A number of novel phosphopeptide antigens have been identified both in vitro as well as on patient tissues. This information has been used to identify potential T-cell targets and by formation of hybridomas we have established a method for expanding specific T-cell's in vitro. Although these hybridomas are currently unstable due to their tetraploid status, we aim to modify this protocol further to allow for stable expansion of hybridoma cells which possess the relevant TCR motif.

Conclusions Identifying a modality for expanding cells with a specific TCR repertoire clearly allows us to target tumour specific phosphopeptide antigens and has the potential to be developed as an immunomodulatory therapy in patients with hepatic tumours or PTLD.

Method We reviewed all the medical reports submitted between January and June 2014 for a Statement of Special Educational Needs (SEN). Additional hospital statistics were collected.

Results Data were analysed on 125 children, 78% boys and 22% girls, median age 6.9 years (1.9–14.8). 65% of children were known to community paediatrics and 25% to CAMHS services. 6% of children were LAC, 5% on CP plan, and 15% excluded from school.

39% children had autism, 7% ADHD, 26% SEMH, 9% physical needs, 8% sensory impairment (all types), 26% SLCN, 46% learning difficulties (all types), 8% SpLDs. 55% of the children had multiple needs, 6% were complex special needs.

In the previous year 62% children attended hospital outpatient (1–16 visits), 10% of children were admitted to hospital (1–4 admissions) and 23% of children had been seen in A&E (1–7 visits). 50% of children were known to hospital specialties, 50% to S&L, 16% physiotherapy, 30% OT services.

Many children had associated health problems (19% medical, 18% nutrition, 9% continence).

Conclusions Children with SEN have extensive health needs and are high users of health services. Our data is likely to be an underestimate as we only analysed hospital statistics and medical reports whose quality varied.

SEN reports provide important health data. Data collection and analysis from a broader range of services continues. The new Education, Health and Care process provides an opportunity for prospective data collection for services planning.

G464(P) TIME TO DISCUSS PREVENTION STRATEGIES FOR GROUP B STREPTOCOCCUS DISEASE

S Salehian, A Rastogi, A Fraisie, O Ghez, M Burmester. Paediatric Intensive Care Unit, The Royal Brompton Hospital, London, UK

Aims Group B Streptococcus (GBS) can cause neonatal septicaemia, meningitis and rarely, infective endocarditis. Through this case study, we aim to raise awareness of the devastating sequelae of GBS disease and the importance of early recognition of complications.

Case discussion: A term infant born in good condition was being managed by the community midwifery team for feeding difficulties, failing to thrive and presented to A&E twice with lethargy and maternal concern. At two weeks of age he represented having additionally developed fever and was admitted and treated for GBS septicaemia and meningitis. He was discharged after 5 days to ambulatory care for continuation of antibiotics. 10 days into treatment his mother became worried and he presented to A&E in cardiogenic shock with a heart murmur, enlarged liver and rising lactate.

Once transferred to the Paediatric Intensive Care Unit, he required ventilation and inotropic support for poor cardiac output, and conservative medical treatment for necrotising enterocolitis, presumed secondary to embolic pathology. An echocardiogram demonstrated two large, mobile masses attached to the mitral valve leaflets with severe mitral regurgitation and right ventricular dysfunction, consistent with infective endocarditis in an otherwise structurally normal heart (Figure 1). Surgical repair of his valve was not possible and so a 17mm prosthetic St Jude’s Valve was placed in the mitral position. Post-operatively he developed a low cardiac output state, seizures, and